Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours Β· Estimated delivery Oct 9 - Oct 14
Spittler also serves as a Denver Nuggets team doctor
New I-MAK Report Exposes Patent Abuse and Market Monopolization Behind GLP-1 Drug Prices The Heavy Price of GLP-1 Drugs reveals how pharmaceutical companies are exploiting the patent system, delaying competition, and driving up costs for patients NEW YORK, April 10, 2025 (Newswire.com) - Today, The Initiative for Medicines, Access, and Knowledge (I-MAK) released a groundbreaking new report, The Heavy Price of GLP-1 Drugs: How Financialization Drives Pharmaceutical Patent Abuse and Health Inequities for GLP-1 Therapies
Administration schedule: Once-daily subcutaneous injection
What's different about pharmaceutical-grade peptides
N.GoldstoneA
US$ 25.95
US$ 29.03
US$ 26.87
